Indian telecom sector has witnessed disruption with entry of Reliance Jio. Investors have witnessed reduction in valuation of their holding in other telecom companies.

Titan's quarterly results disappointed market participants and the stock declined 10 percent after the company gave bleak outlook.

Indian market ended positive on Tuesday and quarterly results are guiding stock specific action.

Indian markets had a strong week and market experts are looking forward to another week of strong action as companies will announce quarterly results.

Panacea Biotec has reported lower quarterly loss at Rs 28 crore compared to the same period last year. The company has managed to reduce its losses and increase its sales revenue to Rs 125 crore compared to Rs 99 crore for the same period last year.

The company also informed that it has received United States Food and Drug Administration (USFDA) approval for Oncology Parenteral Formulations.

Talking about the results, Panacea Biotec MD Rajesh Jain said, "The company's remediation measures have now started paying off. The company has registered impressive financial performance during the quarter ended June 30, 2019 with 28 per cent topline growth and earning positive earnings before interest, taxes, depreciation and amortization (EBITDA) of Rs 26.9 crore."

CESC has declared the results for the three months period ended March 31, 2009.

The company has posted a 9.30% growth in standalone net profit for the fourth quarter ended March 2009.

The company has registered a net profit at Rs 940 million, as against Rs 860 million during the same quarter last year.

Net sales during the period under review surged 18.18% to Rs 7,540 million, whereas total income for the quarter climbed 13.97% to Rs 7,750 million.